Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL in China
Results for the study were first posted on ClinicalTrials.gov on November 10, 2026. The trial enrolled 72 participants who were randomized to receive epcoritamab or investigator's choice chemotherapy for relapsed/refractory diffuse large B-cell lymphoma.
Primary source
ClinicalTrials.gov results record, November 10, 2026
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Read the source: A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation